Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma
Study Details
Study Description
Brief Summary
This study is a survey in Japan of Cabozantinib tablets used to treat people with a type of kidney cancer called renal cell carcinoma. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.
The main aim of the study is to check for side effects from Cabozantinib. During the study, participants with renal cell carcinoma will take Cabozantinib tablets according to their clinic's standard practice. The study doctors will check for side effects from Cabozantinib for 26 weeks.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Detailed Description
The drug being tested in this study is called cabozantinib tablets. This tablet is being tested to treat people who have radically unresectable or metastatic renal cell carcinoma.
This study is an observational (non-interventional) study and will look at occurrence of adverse drug reactions (or adverse events) of cabozantinib tablets in the routine clinical setting. The planned number of observed patients will be approximately 300.
This multi-center observational trial will be conducted in Japan.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Cabozantinib 60 mg Cabozantinib 60 milligrams (mg) tablet, orally, once daily for up to 26 weeks. Participants received interventions as part of routine medical care. |
Drug: Cabozantinib
Cabozantinib tablets
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Number of Participants with Adverse Events Related to Hepatic Failure, Hepatic Dysfunction, and Pancreatitis [Up to 26 weeks]
An adverse event (AE) is any untoward or undesirable medical occurrence in a participant linked in time with the use of a pharmaceutical/ medicinal product. They are not limited to the events with clear causal relationship with treatment with concerned drug. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.
- Number of Participants with Serious Adverse Events [Up to 26 weeks]
A serious AE is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria.
- Number of Participants with Adverse Events Leading to Permanent Treatment Discontinuation with Cabozantinib Tablets [Up to 26 weeks]
- Number of Participants with Grade 3 or higher Adverse Events [Up to 26 weeks]
Severity grade is defined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.
Secondary Outcome Measures
- Percentage of Participants Who Achieve or Maintain Any Best Response Category [Up to 26 weeks]
Best response will be assessed with reference to the excerpts from Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Best response is defined as the level of best response in assessment with complete response (CR), partial response (PR), progressive disease (PD), stable disease (SD) and not evaluable (NE) during the observational period.
Eligibility Criteria
Criteria
Inclusion Criteria:
Patients with radically unresectable or metastatic renal cell carcinoma who do not meet the following exclusion criterion are eligible.
Exclusion Criteria:
A patient who has a history of hypersensitivity to any component of cabozantinib.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Takeda Selected Site | Tokyo | Japan |
Sponsors and Collaborators
- Takeda
Investigators
- Study Director: Study Director, Takeda
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Cabozantinib-5001
- jRCT2031210003